Transparency Market Research has published a new report, titled “Hemophilia Management Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.” While there is no cure for hemophilia, it can be controlled through regular infusions of deficient clotting factor. Therefore, there is a high demand for hemophilia management. This demand is driven by rising number of people suffering from hemophilia, ranging from mild, moderate, to severe hemophilia.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13634
In hemophilia people can bleed to death as patients suffering from hemophilia have a disorder which prevents blood clotting and therefore it is essential to manage haemophilia. Patients suffering from hemophilia, mostly males, suffer from excessive bleeding during surgeries and after injuries.
The rising use of recombinant products and prophylactic regimens is anticipated to bolster the growth of the haemophilia management market. On the other hand, the high cost associated with hemophilia treatment will limit the growth of this market. There are several advanced and effective hemophilia management or treatment options available in the US but they require lifelong infusion of expensive drugs which are manufactured using human plasma or through recombinant biotechnology.
On the basis of geography, Europe is leading in the hemophilia management market followed by North America. Asia Pacific on the other hand, is emerging as a potentially lucrative market for hemophilia management. Market players are advised to invest in this region in order to tap on the unmet medical needs. However the high cost of treatment may act as a hindering factor in Asia-Pacific.
Leading players within the global hemophilia management market are profiled in the report. The names of few are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Grifols International SA, Novo Nordisk A/S, CSL Behring, and Octapharma